SCHEMBL24309639

SCHEMBL24309639

CNC(=O)c1ccc(Oc2cc(Cl)nc(NS(=O)(=O)c3cnn(C)c3)n2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 3/20 0.41
▸ SCN9A Q15858 2/20 0.37
▸ PARP1 P09874 1/20 0.37
▸ HRH1 P35367 1/20 0.36
▸ EGFR P00533 2/20 0.36
▸ FGFR1 P11362 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ KAT6A Q92794 1/20 0.35
▸ KAT5 Q92993 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ CCNC P24863 1/20 0.34
▸ CDK8 P49336 1/20 0.34
▸ TTK P33981 1/20 0.34
▸ MALT1 Q9UDY8 1/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ WNT1 P04628 1/20 0.34
▸ CLK2 P49760 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566701 1.00 HRH3 (0.41) HRH3SCN9APARP1HRH1EGFR
SCHEMBL26807622 0.87 HRH3 (0.43) HRH3SCN9APARP1HRH1JAK1
SCHEMBL26807733 0.86 HRH3 (0.42) HRH3SCN9APARP1HRH1KDR
SCHEMBL29566970 0.86 HRH3 (0.37) HRH3SCN9APARP1HRH1EGFR
SCHEMBL24309468 0.86 HRH3 (0.37) HRH3SCN9APARP1HRH1EGFR
SCHEMBL26810541 0.86 HRH3 (0.39) HRH3SCN9APARP1HRH1EGFR
SCHEMBL26810505 0.86 HRH3 (0.38) HRH3SCN9APARP1HRH1JAK1
SCHEMBL24309812 0.85 HRH3 (0.41) HRH3SCN9APARP1HRH1JAK1
SCHEMBL26807740 0.85 HRH3 (0.40) HRH3SCN9APARP1HRH1FGFR1
SCHEMBL26807590 0.84 HRH3 (0.42) HRH3SCN9APARP1HRH1JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HRH3 4413/4885SCN9A 385/4885PARP1 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback